|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM154 |
Gene summary for TMEM154 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM154 | Gene ID | 201799 |
| Gene name | transmembrane protein 154 | |
| Gene Alias | TMEM154 | |
| Cytomap | 4q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6P9G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 201799 | TMEM154 | LZE4T | Human | Esophagus | ESCC | 2.35e-12 | 2.72e-01 | 0.0811 |
| 201799 | TMEM154 | LZE7T | Human | Esophagus | ESCC | 6.33e-03 | 1.22e-01 | 0.0667 |
| 201799 | TMEM154 | LZE8T | Human | Esophagus | ESCC | 2.72e-03 | 1.23e-01 | 0.067 |
| 201799 | TMEM154 | LZE20T | Human | Esophagus | ESCC | 5.57e-10 | 2.57e-01 | 0.0662 |
| 201799 | TMEM154 | LZE24T | Human | Esophagus | ESCC | 5.64e-10 | 2.37e-01 | 0.0596 |
| 201799 | TMEM154 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.53e-01 | 0.0655 |
| 201799 | TMEM154 | LZE6T | Human | Esophagus | ESCC | 5.26e-07 | 2.56e-01 | 0.0845 |
| 201799 | TMEM154 | P1T-E | Human | Esophagus | ESCC | 5.75e-15 | 5.87e-01 | 0.0875 |
| 201799 | TMEM154 | P2T-E | Human | Esophagus | ESCC | 2.40e-03 | 5.25e-02 | 0.1177 |
| 201799 | TMEM154 | P4T-E | Human | Esophagus | ESCC | 4.58e-21 | 4.26e-01 | 0.1323 |
| 201799 | TMEM154 | P8T-E | Human | Esophagus | ESCC | 1.52e-15 | 2.16e-01 | 0.0889 |
| 201799 | TMEM154 | P9T-E | Human | Esophagus | ESCC | 1.23e-14 | 3.13e-01 | 0.1131 |
| 201799 | TMEM154 | P10T-E | Human | Esophagus | ESCC | 5.52e-18 | 2.44e-01 | 0.116 |
| 201799 | TMEM154 | P11T-E | Human | Esophagus | ESCC | 3.75e-08 | 2.94e-01 | 0.1426 |
| 201799 | TMEM154 | P12T-E | Human | Esophagus | ESCC | 2.32e-12 | 4.88e-01 | 0.1122 |
| 201799 | TMEM154 | P15T-E | Human | Esophagus | ESCC | 3.12e-08 | 1.31e-01 | 0.1149 |
| 201799 | TMEM154 | P16T-E | Human | Esophagus | ESCC | 6.56e-04 | -1.01e-04 | 0.1153 |
| 201799 | TMEM154 | P17T-E | Human | Esophagus | ESCC | 8.50e-05 | 2.60e-01 | 0.1278 |
| 201799 | TMEM154 | P19T-E | Human | Esophagus | ESCC | 2.24e-09 | 4.36e-01 | 0.1662 |
| 201799 | TMEM154 | P20T-E | Human | Esophagus | ESCC | 1.66e-05 | 1.23e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM154 | SNV | Missense_Mutation | rs200120689 | c.61C>T | p.Arg21Trp | p.R21W | Q6P9G4 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TMEM154 | SNV | Missense_Mutation | c.131N>G | p.Thr44Ser | p.T44S | Q6P9G4 | protein_coding | tolerated(0.16) | benign(0.013) | TCGA-AD-6963-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM154 | SNV | Missense_Mutation | c.256T>G | p.Leu86Val | p.L86V | Q6P9G4 | protein_coding | tolerated(0.18) | possibly_damaging(0.766) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM154 | SNV | Missense_Mutation | c.308G>T | p.Arg103Ile | p.R103I | Q6P9G4 | protein_coding | deleterious(0) | possibly_damaging(0.733) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM154 | SNV | Missense_Mutation | novel | c.473G>T | p.Arg158Ile | p.R158I | Q6P9G4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM154 | SNV | Missense_Mutation | rs747209423 | c.427N>A | p.Glu143Lys | p.E143K | Q6P9G4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM154 | SNV | Missense_Mutation | c.198N>A | p.Asn66Lys | p.N66K | Q6P9G4 | protein_coding | tolerated(0.55) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| TMEM154 | SNV | Missense_Mutation | novel | c.296N>T | p.Thr99Ile | p.T99I | Q6P9G4 | protein_coding | tolerated(1) | benign(0.011) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM154 | SNV | Missense_Mutation | novel | c.329N>A | p.Pro110His | p.P110H | Q6P9G4 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM154 | SNV | Missense_Mutation | rs761333606 | c.314N>T | p.Arg105Ile | p.R105I | Q6P9G4 | protein_coding | deleterious(0) | possibly_damaging(0.804) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |